Interní Med. 2005; 7(3): 131-134

Nephrotic syndrome

MUDr. Romana Ryšavá CSc1, doc. MUDr. Vladimír Tesař DrSc2, doc. MUDr. Miroslav Merta CSc2
1 Klinika nefrologie 1. LF UK a VFN, Praha
2 I. interní klinika 1. LF UK a VFN Praha

The review about epidemiology, structural changes in glomeruli, diagnosis, differential diagnosis and therapeutic possibilities in nephrotic syndrome is given. Increased glomerular permeability of the glomerular capillary wall for macromolecules caused by the changes of the structure of the glomerular basement membrane, or podocytes and slit diaphragm between foot processes of podocytes is the main cause of nephrotic syndrome. Recently new information about podocyte proteins (nephrin, podocin, α-actinin 4) and their functions emerged. A deeper understanding of the pathogenesis of hereditary and immunologically based nephrotic syndrome is warranted for installing a rational management. The work-up in the nephrotic syndrome should involve the assessment of albumin-to-creatinine or protein-to-creatinine ratio. The evaluation of the glomerular disease form an integral part of the diagnostic algorithm of the nephrotic syndrome, which unables to fully profit from the complex management of the nephrotic syndrome, involving symptomatic treatment and the treatment of the glomerular disease.

Keywords: Key words: nephrotic syndrome, proteinuria, nephrin, podocin, slit diaphragm.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ryšavá R, Tesař V, Merta M. Nephrotic syndrome. Interní Med. 2005;7(3):131-134.
Download citation

References

  1. Castellino P, Cataliotti A. Changes of protein kinetics in nephrotic patients. Curr Opin Clin Nutr Metab Care., 2002; 5(1): 51-54. Go to original source... Go to PubMed...
  2. Cattran D, et al. Management of Glomerulonephritis. Kidney Int., 55, 1999; (Suppl. 70): S-1-S-62. Go to original source...
  3. Davison A, et al. Oxford Textbook of Clinical Nephrology, 2nd Edition, Oxford Medical Publications, Oxford, 1998: 359-719.
  4. Hilgers KF, Dotsch J, Rascher W, Mann JF. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol., 2004; 19 (9): 956-961. Go to original source... Go to PubMed...
  5. Mogensen CE, Neldan S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper M. for the CALM study group. Randomised controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ, 2000; 321: 1440-1444. Go to original source... Go to PubMed...
  6. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet, 2003; 361: 117-124. Go to original source... Go to PubMed...
  7. Rychlik I, Jančová E, Tesař V, Kolský A, Lacha J, Stejskal J, Stejskalová A, Dušek J, Herout V. The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. Nephrol Dial Transplant., 19(12), 2004: 3040-3049. Go to original source... Go to PubMed...
  8. Silva JM, Oliveira EA, Marino VS, Oliveira JS, Torres RM, Ribeiro AL, Simal CJ, Ribeiro MC. Premature acute myocardial infarction in a child with nephrotic syndrome. Pediatr Nephrol., 2002; 17 (3): 169-172. Go to original source... Go to PubMed...
  9. Tesař V, Zima T, Kalousová M. Novinky v patogenezi nefrotického syndromu. Sborn lék., 103, 2002; 3: 379-395.
  10. Tesař V. Nefrotický syndrom. Lékařské listy, 2003; 31: 7-10.
  11. Wong J, Patel RA, Korey PR. The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis., 2004; 47 (2): 116-130. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.